PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Genuine Impact is the next generation financial terminal made exclusively to empower DIY investors by providing experts with automation tools, portfolio enhancer, unbiased data and insights. Genuine Impact is more cost-effective in comparison with traditional financial terminals, and it makes financial research effortless and efficient. Currently, the company's beta app has 500+ users from more than 27 countries. With the proceeds, the fund raised will be used for new product development, enhancement of existing product and for marketing and branding.
days to go:
Expired
investment:
£500,920
Established in 2011, Crowdcube has become the market leader in the equity crowdfunding sector. The company has a 40% share of the UK market with over 620,000 investors registered on the platform that have invested more than £561m in pitches. This has resulted in nearly 800 successful campaigns and Crowdcube's revenue increasing by 33% from H1 2017 to H1 2018. Funds are being raised to scale the business by expanding further in the UK, as well as overseas.
days to go:
Expired
investment:
£7,918,180
Fairer Finance (FF) is a consultancy launched in 2014, on a mission to become the UK's most trusted provider of consumer financial services ratings. FF makes money through four key channels namely, licensing access to its data and insights, selling endorsements to those who do well in its ratings, sponsored research that helps improve the financial services market, and helping firms do better for their customers. FF earned £170,000 worth of revenues in its latest quarter, had its ratings published on thetimes.co.uk, which got 35 million views/week and onboarded noted entity, Lloyds Bank, that uses FF's data insights. The company aims to expand into more banking and insurance sectors and grow its consumer presence, helping it to strike deals with comparison sites and sign up more companies for its Insight services. The company will use the investment to expand its campaigning work and create a fairer market for consumers.
days to go:
Expired
investment:
£291,899
HubrisOne is an online platform that allows its global customers to exchange, invest and safely store their crypto assets, tapping into a $500bn+ global digital asset market. Their aim is to simplify the world of digital currencies and blockchain technology by focusing on product design, user experience, and consistent innovation. Till date, they have engaged over 100,000 members and started generating revenues since its launch in July 2019. The funds will be used in product development, expanding the team, salaries and marketing.
days to go:
Expired
investment:
£903,990
Avida Global (AG) is a Business-to-Business (B2B) producer of high-quality medicinal cannabis oils and derivatives for the global medical, well-being and cosmeceutical markets. The company has a cultivation and processing facility in North-East Colombia. It asserts that the therapeutic properties of the cannabis plant has driven 53 countries to legalise its use, with more to follow. AG seeks to capture this demand and become a contender in the medicinal cannabis market that is expected to soar from $33.1 billion to $84.0 billion by 2028. The company has received regulatory approvals for initial non-psychoactive cannabis cultivation, manufacturing, and export licences in 2019. It is working on a partnership with a medicinal cannabis prescriber through doctors and clinics for the supply of medicinal cannabis strains in the UK. The company will use 40% of the investment to drive revenue growth, 25% as capital expenses, and 35% as additional operating expenses.
days to go:
Expired
investment:
£1,646,249
The Bottled Bartender is a manufacturer of premium RTD cocktails. The company manufactures, markets, and distributes single-serve premium cocktails to the trade, events and home markets. The cocktails are designed with the same recipes as a high-end bar, by using only branded spirits, garden-fresh ingredients made by the experienced staff. The company wants Trade and Events to benefit from the speed of service and logistical ease and not hire specialist staff. The Bottled Bartender anticipates in using a 24-hour courier service.
days to go:
Expired
investment:
£61,150
